Premium
Syntheses of Platinum–Sulindac Complexes and Their Nanoparticles as Targeted Anticancer Drugs
Author(s) -
Hwu Jih Ru,
Tsay ShwuChen,
Chuang Kao Shu,
Kapoor Mohit,
Lin Jia Yu,
Yeh ChenSheng,
Su WuChou,
Wu PingChing,
Tsai TsungLin,
Wang PeiWen,
Shieh DarBin
Publication year - 2016
Publication title -
chemistry – a european journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.687
H-Index - 242
eISSN - 1521-3765
pISSN - 0947-6539
DOI - 10.1002/chem.201504915
Subject(s) - sulindac , chemistry , plga , glycolic acid , platinum , ic50 , pharmacology , stereochemistry , biochemistry , lactic acid , in vitro , medicine , biology , nonsteroidal , bacteria , genetics , catalysis
Platinum(II)–sulindac complexes [{η 2 ‐C 5 H 4 SN(O)}Pt(DMSO){O(C=O)Sulindac}], [{η 2 ‐C 5 H 4 SN(O)}PtCl{(S=O)Sulindac}], [{η 2 ‐C 5 H 4 SN(O)}PtCl{(S=O)Sulindac–succinimide}], and [{η 2 ‐C 5 H 4 SN(O)}PtCl{(S=O)Sulindac–thymidine}] were synthesized that exhibited IC 50 values of 2.9–4.8 μ m against human oral cancer cells OECM1. The poly(lactic‐ co ‐glycolic acid) (PLGA) encapsulated [{η 2 ‐C 5 H 4 SN(O)}PtCl{(S=O)Sulindac}] also showed cytotoxic activity although less potent than the pristine species.